anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fluoroquinolones, including levofloxacin, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. Severe cases of hypoglycemia resulting coma or death have been reported. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, discontinue levofloxacin and initiate appropriate therapy immediately , . Fluoroquinolones, including levofloxacin, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. Severe cases of hypoglycemia resulting in coma or death have been reported. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, discontinue levofloxacin and initiate appropriate therapy immediately [see Adverse Reactions (6.1),  Drug Interactions (7.3) and Patient Counseling Information (17)] .
The technique of Endoscopic Mucosal Resection (EMR) is currently widely used in the US to remove precancerous or cancerous lesions confined to the mucosa of the GI tract. EMR carries lower morbidity and mortality compare to surgery, at the expense of a higher rate of piecemeal removal, incomplete resection and cancer recurrence. Endoscopic Submucosal Dissection (ESD) is a newer technique developed in Japan that involves en-bloc resection of the entire lesion irrespective of size, allowing for a detailed analysis of the resected margins and depth of invasion and producing a lower local recurrence. Due to the lack of dedicated ESD devices the procedure has not been disseminated in Western countries. Recently the Food and Drug Administration (FDA) approved a number of devices for ESD. The vast majority of studies evaluating the clinical outcomes from ESD are originating in Japan where the technique is mostly applied to patients with early gastric cancer (Japan has the highest incidence of gastric cancer in the word). In the US lesions that are currently treated with EMR are mostly located in the esophagus (Barrett esophagus) and colon (large adenomatous polyps and intramucosal cancer). These esophageal and colonic lesions can be treated with ESD with expected higher rate of en-block resection and lower recurrence rate compare to EMR. With the differences in patient population and disease location one can anticipate some differences in outcomes between ESD performed in Asian and US patients. Therefore, the investigator wants to prospectively record the experience with ESD done as part of routine medical care in United States (US) population. This will be a prospective data recording study. All patients will receive standard medical care and no experimental interventions will be performed.
The present invention relates to a personal care article for providing at least two liquid personal care compositions. The personal care article comprises a single chamber package and a liquid personal care product. The package comprises a dispensing orifice, a first zone proximate to the dispensing orifice and a second zone distal to the dispensing orifice. The liquid personal care product comprises a first personal care composition substantially disposed within the first zone and the second personal care composition substantially disposed within the second zone. The first personal care composition comprises a first concentration of hydrophobic benefit material. The second personal care composition comprises a second concentration of hydrophobic benefit material. The first concentration of hydrophobic benefit material is different from the second concentration of hydrophobic benefit material.
BACKGROUND: Although patients with paroxysmal atrial fibrillation (PAF) are preferred to undergo catheter ablation (CA), the high possibility of recurrence following surgery is still concerning. We aimed to evaluate the ability of the left atrioventricular coupling index (LACI), which is the ratio of the left atrium end-diastolic volume to the left ventricle end-diastolic volume, to predict PAF recurrence after CA.
METHODS: Patients with PAF undergoing CA for the first time between January 2018 and June 2021 were admitted and grouped by recurrence within a year. LACI was measured before CA using ultrasonography. Risk factors identified by multivariable logistic regression analysis, and the area under the receiver operating characteristic (ROC) curve was used to assess the ability of LACI to predict PAF recurrence after CAP.
RESULTS: Among the 204 patients treated at our hospital, 164 patients were included in the research after eliminating those who were lost to follow-up. Among them, 56 individuals had recurrence following a 90-day blanking period. Recurrence is more likely in elderly patients with high blood pressure. Patients who suffered recurrence exhibited lower left atrial ejection fraction and increased LACI, left atrial volume minimum, and left atrium volume index maximum. LACI was an independent risk factor for postoperative recurrence (OR: 1.526, 95% CI: 1.325-1.757, P < 0.001), and ROC displayed remarkable predictive value [area under the curve (AUC) = 0.868].
CONCLUSIONS: High LACI is significantly associated with postoperative recurrence in PAF patients, and LACI has incremental prognostic value to predict recurrence.
The invention relates to an injection for treating swine enzootic pneumonia and a preparing method thereof. Main components and contents of the injection are as follows: each 100 L of the injection contains 5-20 kg of thiamphenicol, 10-30 L of dimethylacetamide, and 0.5-5 kg of doxofylline, with the balance being propylene glycol. The preparing method includes: (1) weighing the thiamphenicol, adding the thiamphenicol into the dimethylacetamide and stirring; (2) adding the doxofylline into the propylene glycol, heating, stirring for 10-30 min until the doxofylline is dissolved; and (3) combining the solutions prepared in the step (1) and the step (2). The injection adopts a composite preparation combining the thiamphenicol that is an antibacterial drug and the doxofylline that is a bronchodilator. Curative effects of the injection for swine mycoplasmas are obviously improved. The injection can obviously relieve various clinical symptoms caused by swine mycoplasma infection. Experiments prove that: synergy of the thiamphenicol and the doxofylline has good curative effects for enzootic pneumonia caused by the swine mycoplasmas, is wide in clinical application, and can relieve the problem of medicine residue caused by large dosages when a single medicine is used.
Cognitive deficits have been considered as a core symptom domain of schizophrenia. Amelioration of or improvement in cognitive impairments is becoming an important focus of clinical treatment development. Varenicline is a potent and selective alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist that has been developed for smoking cessation. In animal studies, alpha 4 beta 2 receptor agonists significantly improve working memory and attention function. Subjects will be assigned in 1:1 ratio to receive varenicline or placebo respectively. Assessments will be done using several neuropsychologic tests, clinical rating scale including assessment of nicotine withdrawal scales.Varenicline has been found to be efficacious for smoking cessation in the general population and animal studies have demonstrated the cognitive benefits of this agent. However, no published work is available evaluating the cognitive effects in humans. Thus, patients may experience improvements in cognitive function and in people who are smokers, these people may be able to achieve abstinence in smoking. This will in turn improve long-term functional outcomes and health outcomes in people with schizophrenia. This is an exciting opportunity for discovery if indeed cognitive abilities could be improved with this adjunctive treatment.
In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods will be applied. Participants will receive exercise training 5 days a week for 6 weeks. Manual therapy methods will be used 2 days a week for the first 2 weeks and then 1 day a week.
<P>PROBLEM TO BE SOLVED: To provide a mineral-containing toilet soap gentle to the skin of a human and useful for the health of the skin by using it in bathing/washing face.  <P>SOLUTION: This solid toilet soap contains 1.5-10 wt. % granite porphyry, 0.5-5 wt. % olive oil and 0.1-3 wt. % turmeric. The soap is useful for the health and beautiful whitening of the skin such as the prevention of skin roughness and improvement of dry skin and atopic sensitive skin, etc., by using it for the bathing, washing face, etc., exhibits no incompatibility by containing minerals on using, and can be used with a refreshing feeling. Also it effectively exhibits a larger effect by an interactive action of the mineral components with other additive components.  <P>COPYRIGHT: (C)2004,JPO
Participants will receive JNJ-40411813 matching placebo (bid) up to 12 weeks. Participants will also receive concomitant AEDs one of which must include levetiracetam or brivaracetam during double blind period. Participants who had been receiving placebo in double blind period will start with the JNJ-40411813 dose in the OLE period.
Patients are given azacytidine for 7 days, followed by 4 DLI treatments on Days 10, 17, 24 and 31, with the dose of DLI and Camrelizumab adjusted according to the donor source. Camrelizumab infusions were given 3 hours after completion of the 1st and 3rd DLIs, respectively.
The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
1. The use of combination of angiotensin converting enzyme (ACE) inhibitor and diuretic for obtaining pharmaceutical compositions for treatment of arteriolo capillary microcirculation loss. 2. The use according to Claim 1, characterized in that angiotensin converting enzyme (ACE) inhibitor is perindopril, captopril, enalapril, lisinopril, delapril, fosinopril, quinapril, ramipril, spirapril, imidapril, trandolapril, benazepril, cilazapril or temocapril and diuretic is indapamide, hydrochlorothiazide, furosemide, altizide, trichlormethiazide, triflumethazide, bemetizide, cyclothiazide, methylclothiazide, azosemide, chlorothiazide, butizide, bendrofluazide, cyclopenthiazide, benzchlortriazide, polythiazide, hydroflumethazide, benzthiazide, ethiazide, penflutazide, clopamide, cicletanide or piretanide, as well as addition salts thereof, formed with pharmaceutically acceptable acid or base. 3. The use according to Claim 1, characterized in that angiotensin converting enzyme (ACE) inhibitor is perindopril, captopril, enalapril, lisinopril, benazepril, quinapril or delapril and diuretic is indapamide, hydrochlorothiazide, as well as addition salts thereof with pharmaceutically acceptable acid or base. 4. The use of combination of perindopril converting enzyme inhibitor and one of its addition salts of pharmaceutically acceptable base, and diuretic is indapamide for obtaining pharmaceutical composition for treatment of arteriolo capillary microcirculation loss. 5. The use according to Claim 4, characterized in that converting enzyme inhibitor is tert-butylamine salt of perindopril and diuretic is indapamide. 6. The use according to Claim 4, characterized in that pharmaceutical composition comprises tert-butylamine salt of perindopril and indapamide in amounts respectively from 65 to 85% and from 35 to 15 % counting on active principles mass. 7. The use according to Claim 6, characterized in that the composition comprises tert-butylamine salt of perindopril in the amount of 76 % and indapamide in the amount of 24 %. 8. The use according to Claim 1, characterized in that pharmaceutical composition is in the form of tablets. 9. The use according to Claim 4, characterized in that pharmaceutical composition is in the form of tablets. 10. The pharmaceutical composition for use according to Claim 9, characterized in that a tablet comprises 2 mg of tert-butylamine salt of perindopril and 0,625 mg of indapamide and pharmaceutically acceptable non-toxic, inert diluents or carriers. 11. The pharmaceutical composition for use according to Claim 9, characterized in that a tablet comprises 4 mg of tert-butylamine salt of perindopril and 1,25 mg of indapamide and pharmaceutically acceptable non-toxic, inert diluents or carriers.
The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
A ready to use clove oil formulation for anesthesia for aquatic animals comprises an effective amount of a preparation comprising clove oil, polyethylene glycol 400, propylene glycol, ethyl alcohol, and surfactant to anesthesize, reduce mobility and reduce the rate of metabolism, wherein said preparation can dissolve and distribute well in water (i.e. presenting no floating clove oil on the water surface). The formulation also comprises of other pharmaceutical aids e.g. anti-oxidative agents, chelating agents, preservative agents and coloring agents. The anti-oxidative agents are phenolic antioxidants as well as reducing agents (e.g. ascorbic acid, ascorbyl palmitate, etc.). Examples of the chelating agent are citric acid, disodium ethylenediaminetetraacetic acid (Disodium EDTA). Examples of the preservative agents are parabens, benzyl alcohol, chlorobutanol, thiomersal, nitromersol, benzalkonium chloride, cetylpyridinium chloride. The coloring agents are water-soluble coloring agents (dyes).
An injector (100) includes a push rod, a magazine tube, a gate, a cannula (122) and an actuator (170). The magazine tube has a lumen extending from an inlet to an outlet thereof. The magazine tube slidingly receives at least one implant therein. The gate has a closed configuration in which it covers the outlet of the magazine tube and an open configuration in which it does not cover the outlet of the magazine tube. The cannula (122) has a distal end (123) configured to be inserted into an eye. A lumen of the cannula (122) is in fluid communication with the lumen of the magazine tube when the gate is in the open configuration. Actuation of the actuator (170) moves the gate from the closed configuration to the open configuration and causes translation of the pushrod through the magazine tube and the cannula (122).
The intervention group will likely consist of one to two sessions, conducted in-person, coupled with text- or phone-based client navigation.The intervention group will complete three major assessments: baseline (T1), at the conclusion of the intervention (T2), and a six-month follow-up (T3). Until the follow-up assessment, the interventionist will send participants up to 6 SMS messages (one-way) per month. The content of these messages will be developed collaboratively between the participant and the interventionist during the second session; messages could include reminders about follow-ups and/or prompts to use new skills and resources for navigating specific barriers.
The invention discloses a new application of tanshinone IIA. Tanshinone IIA is one of main effective components in tanshinone, has a quinoid structure, is easy to be oxidized and reduced, can participate in various biochemical reactions in human body and has various biological activities. Tanshinone IIA has various pharmacological effects, can resist cardiac muscle acute hypoxic injury, resist arrhythmia, improve blood vessel smooth muscle functions, and has protection effect on tissue damage caused by ischemia-reperfusion. According to the invention, tanshinone IIA can reduce the arsenic content in body blood. Arsenic is a toxic substance with severe harm to human body. Research shows that when compared with a blank control group, rats administrated with tanshinone IIA have obviously reduced arsenic concentration in blood.
Until now, biodegradable depot formulations that release active ingredients in the body of animals and humans in a controlled manner have been primarily polymer based. One disadvantage of these polymers is the complexity of the polymer degradation. The new depot formulations are designed to be non polymer based, injectable, and to release active ingredients in a controlled manner over a period of days to months. The active ingredient formulations should be formed by chemically stable, well-tolerated, and biodegradable or eliminable ingredients. The invention relates to the development of injectable lipophilic preparations. Said preparations are based on an oily component with 12-hydroxystearic acid as the gelling agent, and enable the controlled release of active ingredients that can exist in a dissolved, emulsified or suspended form. The formulations are suitable for use in treatments in human and veterinary medicine.
Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
INTRODUCTION: Perinatal asphyxia, a leading cause of neonatal mortality and neurological sequelae, necessitates early detection of pathophysiological neurologic changes during hypoxic-ischaemic encephalopathy (HIE). This study aimed to review published data on rScO2 monitoring during hypothermia treatment in neonates with perinatal asphyxia to predict short- and long-term neurological injury.
METHODS: A systematic review was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study identification was performed through a search between November and December 2021 in the electronic databases PubMed, Embase, Lilacs, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL). The main outcome was short-term (Changes in brain magnetic resonating imaging) and long-term (In neurodevelopment) neurological injury. The study protocol was registered in PROSPERO (International Prospective Register of Systematic Reviews) with CRD42023395438.
RESULTS: 380 articles were collected from databases in the initial search. Finally, 15 articles were selected for extraction and analysis of the information. An increase in rScO2 measured by NIRS (Near-infrared spectroscopy) at different moments of treatment predicts neurological injury. However, there exists a wide variability in the methods and outcomes of the studies.
CONCLUSION: High rScO2 values were found to predict negative outcomes, with substantial discord among studies. NIRS is proposed as a real-time bedside tool for predicting brain injury in neonates with moderate to severe HIE.
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention proposes phytopreparation containing an alcoholic tincture at the following ratio of components, wt.-%: elfwort roots 2-5; marsh cinquefoil roots 1-4; birch buds 0.5-1.5, and 40-70% ethyl alcohol - the rest. Pantocrin or ginseng alcoholic tinctures can be added to this tincture also. Preparation "Alevalon" can be prepared as dry one and used both for oral and external using in combination with any pharmaceutical base. Method of preparing involves by turn addition of indicated components at heating and periodic shaking of tincture. EFFECT: enhanced effectiveness of preparation. 5 cl, 1 tbl
At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate \>100 bpm and preductal oxygen saturation \>85%, while using an fraction of inspired oxygen (FiO2) of \<0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
The cytokine storm induced by duck hepatitis A virus type 1 (DHAV-1) infection significantly contributes to severe, rapid deaths and economic losses in the duck industry in Egypt. This study aimed to investigate the potential inhibitory effect of a nanoemulsion containing turmeric and black pepper oil on the immune response and pathogenesis of DHAV-1 in ducklings. A total of 105 ducklings from nonvaccinated breeders were divided into 5 experimental groups, each comprising 21 birds. The negative control group (G1) remained noninfected with DHAV-1 and nontreated with nanoemulsion, while the positive control group (G2) was infected with DHAV-1 but not treated with nanoemulsion. The other 2 groups (G3, the supplemented group which was noninfected with DHAV-1), and group 4 (the prophylactic group G4) which was infected with DHAV-1, both received nanoemulsion throughout the experiment. Group 5 (G5, the therapeutic group), on the other hand, which was infected with DHAV-1 received nanoemulsion only from the onset of clinical signs. At 5 days old, the ducklings in the positive control (G2), the prophylactic (G4), and the therapeutic group (G5) were infected with DHAV-1. All the ducklings in the infected groups exhibited depression, anorexia, and opisthotonos, and their livers displayed various degrees of ecchymotic hemorrhage, liver enlargement, and microscopic pathological lesions. Notably, the positive control group (G2) experienced the most severe and pronounced effects compared to the other infected groups treated with the nanoemulsion. Meanwhile, the viral RNA loads were lower in the liver tissues of the infected ducklings treated with the nanoemulsion (G4, and G5) compared to the positive control group G2. Additionally, the nanoemulsion effectively modulated proinflammatory cytokine expression, antioxidant enzymes, liver enzymes, and lipid profile of treated ducklings. In conclusion, the turmeric and black pepper oil nanoemulsion has the potential to be a therapeutic agent for regulating and modulating the immune response, decreasing DHAV-1-induced cytokine storms, and minimizing mortality and economic losses in the duck business. More research is needed to understand how turmeric and black pepper oil nanoemulsion alleviates DHVA-1-induced cytokine storms and lowers duckling mortality.